Overview

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Status:
Terminated
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Ustekinumab